Clearstate Pte. Ltd.
and
United BioSource Corporation (UBC)
announced a strategic partnership to provide global market access, pricing, and reimbursement strategies for manufacturers of biopharmaceuticals, medical devices, and other medical technology.
The agreement reinforces Clearstate’s position as a source for accurate and actionable market intelligence across the Asia-Pacific region and builds upon UBC’s leadership in delivering global market access strategies for life science products. The alliance provides UBC and its clients with access to the high quality market access, pricing, and reimbursement information.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.